Sirona Biochem Corp. (SBM) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Jun 2023)

FII

0.00%

Held by 0 FIIs

DII

Held by 0 DIIs

Promoter

10.42%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals: Major

Market cap

CAD 16 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.95

Return on Equity

76.97%

Price to Book

-4.57

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jul 2024)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-14.29%

6 Months

-33.33%

1 Year

-29.41%

2 Years

-36.84%

3 Years

-70.0%

4 Years

-87.5%

5 Years

-81.54%

Sirona Biochem Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-4.61%

EBIT Growth (5y)

5.79%

EBIT to Interest (avg)

-3.40

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.95

Sales to Capital Employed (avg)

0.27

Tax Ratio

10.40%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-4.57

EV to EBIT

-7.25

EV to EBITDA

-7.27

EV to Capital Employed

-19.10

EV to Sales

-19.10

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2023

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jul'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jul 2024 is 0.00% vs 0.00% in Apr 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jul 2024 is -125.00% vs 42.86% in Apr 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jul'24",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.70",
          "val2": "-0.50",
          "chgp": "-40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.90",
          "val2": "-0.40",
          "chgp": "-125.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-295,313.40%",
          "val2": "-48,228.00%",
          "chgp": "-24,708.54%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Oct'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Oct 2023 is -100.00% vs 133.33% in Oct 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Oct 2023 is 30.56% vs -56.52% in Oct 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Oct'23",
        "Oct'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.70",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.90",
          "val2": "-3.90",
          "chgp": "25.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.50",
          "val2": "-3.60",
          "chgp": "30.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-82,309.00%",
          "val2": "-5,872.90%",
          "chgp": "-7,643.61%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jul'24 - QoQ

Jul'24

Apr'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.70

-0.50

-40.00%

Interest

0.20

0.00

Exceptional Items

0.00

Consolidate Net Profit

-0.90

-0.40

-125.00%

Operating Profit Margin (Excl OI)

-295,313.40%

-48,228.00%

-24,708.54%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jul 2024 is 0.00% vs 0.00% in Apr 2024

Consolidated Net Profit

QoQ Growth in quarter ended Jul 2024 is -125.00% vs 42.86% in Apr 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Oct'23

Oct'23

Oct'22

Change(%)

Net Sales

0.00

0.70

-100.00%

Operating Profit (PBDIT) excl Other Income

-2.90

-3.90

25.64%

Interest

0.20

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.50

-3.60

30.56%

Operating Profit Margin (Excl OI)

-82,309.00%

-5,872.90%

-7,643.61%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Oct 2023 is -100.00% vs 133.33% in Oct 2022

Consolidated Net Profit

YoY Growth in year ended Oct 2023 is 30.56% vs -56.52% in Oct 2022

All Annual Results

Company CV

About Sirona Biochem Corp.

Sirona Biochem Corp.

Pharmaceuticals: Major

Sirona Biochem Corp. is a Canada-based development-stage cosmetic ingredient and drug discovery company with a technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. It is engaged in the development of cosmetic and pharmaceutical active ingredients, which are licensed to its partners. The Company has six product lines: SGLT2 Inhibitor, Skin Lightener I, GlycoProteMin-Anti aging, Anti-inflammatory, Anti-infective and Skin Lightener II. Its development is focused on three programs: therapeutics, which includes diabetes, anti-inflammatories and anti-infectives; cosmeceuticals, which includes anti-aging and depigmenting agents (skin lighteners), and biological ingredients, which includes inducers and adjuvants for biological development and preservation. The Company, through TFChem S.A.R.L. (TFC), is engaged in using fluorine atom properties to develop glycomimetic compounds.

Company Coordinates

Company Details

Sirona Biochem Corp. (c/o WeWork), 595 Burrard St. VANCOUVER BC : V7X 1L3

Tel: 1 604 6414466

http://www.sironabiochem.com/

Registrar Details